NILVAD protocol: A European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease

BMJ Open

Volumn 4, Issue 10, 2014, Pages

  Lawlor, Brian ^a   Kennelly, Sean ^a   O'Dwyer, Sarah ^a   Cregg, Fiona ^b   Walsh, Cathal ^b   Coen, Robert ^a   Kenny, Rose Anne ^a   Howard, Robert ^c   Murphy, Caroline ^c   Adams, Jessica ^c   Daly, Leslie ^d   Segurado, Ricardo ^d   Gaynor, Siobhan ^e   Crawford, Fiona ^f   Mullan, Michael ^f   Lucca, Ugo ^g   Banzi, Rita ^g   Pasquier, Florence ^h   Breuilh, Laetitia ^h   Riepe, Matthias ⁱ   Kalman, Janos ^j   Wallin, Anders ^k   Borjesson, Anne ^k   Molloy, William ^l   Tsolaki, Magda ^m   Olde Rikkert, Marcel ⁿ   more..

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e Molecular Medicine Ireland   (Ireland)

^f Archer Pharmaceuticals Inc   (United States)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF ULM   (Germany)

^j UNIVERSITY OF SZEGED   (Hungary)

^k UNIVERSITY OF GOTHENBURG   (Sweden)

^l UNIVERSITY COLLEGE CORK   (Ireland)

^m ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NILVADIPINE; PLACEBO; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE;

ADULT; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DISABILITY ASSESSMENT FOR DEMENTIA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED RELEASE PREPARATION; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; EUROPE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84911435297     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006364     Document Type: Article

References (19)

1. Lang NP, , Adler R, , Joss A, , et al. Absence of bleeding on probing. An indicator of periodontal stability. J Clin Periodontol 1990;17:714-21. [CrossRef] [Medline] [Web of Science]
2. Ohtsuka M, , Ono T, , Hiroi J, , et al. Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists. J Cardiovasc Pharmacol 1983;5:1074-82. [Medline] [Web of Science]
3. Paris D, , Bachmeier C, , Patel N, , et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the bloodbrain barrier. Mol Med 2011;17:149-62. [Medline]
4. Furuichi Y, , Takakura S, , Satoh H, , et al. The effect of nilvadipine, a dihydropyridine type calcium channel blocker, on local cerebral blood flow in rats. Jpn J Pharmacol 1992;58:457-60. [Medline]
5. Inouye M, , Mio T, , Sumino K. Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis. Eur J Clin Pharmacol 2000;56:35-41. [Medline]
6. Kagawa H, , Nomura S, , Ozaki O, , et al. Effects of nilvadipine on cytokine levels and soluble factors in collagen complicated with essential hypertension. Clin Exp Hypertens 1999;21:1177-88. [Medline]
7. Forette F, , Seux ML, , Staessen JA, , et al. Prevention of dementia in randomized double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51. [CrossRef] [Medline] [Web of Science]
8. Yasar S, , Corratta M, , Brookmeyer R, , et al. Calcium channel blockers and risk of AD: the Baltimore longitudinal study of aging. Neurobiol Aging 2005;26:157-63. [CrossRef] [Medline] [Web of Science]
9. Hanyu H, , Hirao K, , Shimizu S, , et al. Nilvadipine prevents cognitive decline in patients with mild cognitive impairment. Int J Geriatr Psychiatry 2007;22:1264-6. [CrossRef] [Medline]
10. Kennelly S, , Abdullah L, , Kenny RA, , et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial. Int J Geriatr Psychiatry 2012;27:415-22. [Medline]
11. Kennelly SP, , Abdullah L, , Paris D, , et al. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry 2011;10:1038-45.
12. McKhann G, , Drachman D, , Folstein M, , et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. [CrossRef] [Medline]
13. Forette F, , Seux ML, , Staessen JA, , et al; Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046-52. [CrossRef] [Medline] [Web of Science]
14. López-Arrieta JM, , Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;(3):CD000147.
15. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27:1133-42. [CrossRef] [Medline] [Web of Science]
16. Gold M. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psyhiatry 2007;63:3.
17. Alzheimer's Association, 2010 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia, 2010 Volume 6. 2010. http://www.alz.org
18. Hampel H, , Prvulovica D, , Teipe S, , et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 2011;95:718-28. [CrossRef] [Medline]
19. Mancia G, , De Backer G, , Dominiczak A, , et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536. [FREE Full text]